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Abstract
Current therapy for chronic kidney disease (CKD) is unsatisfactory because of an insufficient understanding of its pathogenesis. Matrix
remodelling-associated protein 5 (MXRA5, adlican) is a human protein of unknown function with high kidney tissue expression, not pre-
sent in rodents. Given the increased expression of MXRA5 in injured tissues, including the kidneys, we have suggested that MXRA5
may modulate kidney injury. MXRA5 immunoreactivity was observed in tubular cells in human renal biopsies and in urine from CKD
patients. We then explored factors regulating MXRA5 expression and MXRA5 function in cultured human proximal tubular epithelial cells
and explored MXRA5 expression in kidney cancer cells and kidney tissue. The fibrogenic cytokine transforming growth factor-b1 (TGFb1)
up-regulated MXRA5 mRNA and protein expression. TGFb1-induced MXRA5 up-regulation was prevented by either interference with
TGFb1 activation of the TGFb receptor 1 (TGFBR1, ALK5) or by the vitamin D receptor agonist paricalcitol. By contrast, the pro-inflam-
matory cytokine TWEAK did not modulate MXRA5 expression. MXRA5 siRNA-induced down-regulation of constitutive MXRA5 expression
resulted in higher TWEAK-induced expression of chemokines. In addition, MXRA5 down-regulation resulted in a magnified expression of
genes encoding extracellular matrix proteins in response to TGFb1. Furthermore, in clear cell renal cancer, von Hippel–Lindau (VHL) reg-
ulated MXRA5 expression. In conclusion, MXRA5 is a TGFb1- and VHL-regulated protein and, for the first time, we identify MXRA5 func-
tions as an anti-inflammatory and anti-fibrotic molecule. This information may yield clues to design novel therapeutic strategies in
diseases characterized by inflammation and fibrosis.
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Introduction
Chronic kidney disease (CKD) is defined as abnormalities of kidney
structure or function, present for more than 3 months, with implica-
tions for health [1]. Indeed, CKD is among the fastest growing causes
of death worldwide and is a major cause of disability [2, 3]. Mortality
results both from accelerated cardiovascular disease and from pro-
gression to end-stage renal disease (ESRD). ESRD patients require
lifelong dialysis or kidney transplantation and have a mortality which
is 10- to 100-fold higher than the general population [4]. Renal
inflammation and fibrosis are key pathological processes involved in
the progression of CKD to ESRD. Current therapy for CKD is unsatis-
factory and has failed to prevent the increase in CKD-associated mor-
tality. Anti-proteinuric agents targeting the renin–angiotensin system
have been the backbone of kidney disease therapy for almost
30 years [5]. However, as exemplified by diabetic nephropathy, the
most common cause of ESRD worldwide, promising new drugs usu-
ally fail key phase 2 or phase 3 trials [6]. Thus, an improved under-
standing of the pathogenesis of CKD and, specifically, of the
molecules governing the transition to chronicity is needed in order to
design novel therapeutic approaches to CKD [7].
Inflammation is a key promoter of CKD progression, eventually
leading to renal fibrosis. Renal fibrosis arises from imbalances in
extracellular matrix (ECM) homoeostasis, leading to ECM accumula-
tion. Renal fibrosis is the strongest histological predictor of CKD pro-
gression, regardless the cause of the primary disease [8]. Among the
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Fig. 1 The MXRA5 gene. (A) Gene tree representing MXRA5 orthologues. The display shows the maximum likelihood phylogenetic tree representing
the evolutionary history of gene. Note the existence of a human gene (Ensembl: accessed on January 25th). (B) MXRA5 gene expression in diverse
human organs according to publicly accessible databases. Note high kidney MXRA5 mRNA levels as compared to other organs (n = 10, *P < 0.001
versus Universal RNA; source: GEO 17426686, 4689086). (C) Correlation between MXRA5 and Fn14 (TNFRSF12A) mRNA expression in human focal
segmental glomerulosclerosis according to publicly accessible databases. Source: Nephromine [21].
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multiple factors contributing to kidney inflammation and fibrosis,
agents targeting the inflammatory cytokine TWEAK and the fibrogenic
protein TGFb1 have reached the clinical trial stage, albeit not yet
successfully [9, 10]. TWEAK activation of Fn14 promotes podocyte
injury [11], tubulointerstitial inflammation [12] and interstitial fibrosis
[13], while TGFb1 promotes fibrosis and dampens inflammation, pro-
moting the scarring process as resolution of inflammation.
Matrix remodelling-associated protein 5 (MXRA5), also known as
adhesion protein with leucine-rich repeats and immunoglobulin
domains related to perlecan (Adlican), is a protein of unknown func-
tion belonging to the MXRA gene family. The MXRA5 gene encodes a
protein of a predicted molecular weight of 312 kDa. The MXRA family
comprises three genes (MXRA5, MXRA7 and MXRA8) and is thought
to participate in cell adhesion and matrix remodelling [14]. MXRA5 is
found in primates, marsupials, some mammals, birds and fishes, but
not in mouse or rat. MXRA5 mRNA is up-regulated in human chronic
ischaemic myocardium, together with other genes promoting ECM
remodelling [15] and in fibroblast primary cultures from centenarians
[16]. Although MXRA5 functions are not well known, these data point
to a potential role in tissue injury and fibrosis. The kidney is among
the highest MXRA5 expressing organs (http://www.ncbi.nlm.nih.gov/
IEB/Research/Acembly/av.cgi?db=human&q=MXRA5; accessed May
15, 2016). Thus, we hypothesized that MXRA5 may play a role in kid-
ney inflammation or fibrosis and we now report on the factors regu-
lating MXRA5 expression in kidney tubular cells and, for the first
time, on MXRA5 function.
Materials and methods
Ethics
The IIS–Fundacion Jimenez Dıaz Biobank is part of the ISCIII Network
of Biobanks. The biobank and biobank consent forms have been
approved by the Ethics Committee of the IIS-Fundacion Jimenez Dıaz
and patients who donated samples signed an informed consent form.
The current project was also approved by the Ethics Committee of the
IIS-Fundacion Jimenez Dıaz and conforms to the Declaration of Helsinki
and current Spanish legislation.
Cells and reagents
HK-2 human proximal tubular epithelial cells (ATCC, Rockville, MD, USA)
were grown on RPMI 1640 (Life Technologies, Grand Island, NY, USA)
with 10% heat-inactivated FBS, 2 mM glutamine, 100 U/ml penicillin,
100 lg/ml streptomycin, 5 lg/ml insulin, 5 lg/ml transferrin, 5 ng/ml
sodium selenite and 5 ng/ml hydrocortisone in 5% carbon dioxide at 37°C
[17]. VHL-defective clear cell renal carcinoma cells (VHL/ ccRCC) and
VHL+/+ ccRCC cells have been previously described [18]. For experi-
ments, cells were rested in serum-free media 24 hr prior to the addition of
stimuli and throughout the experiment. Five hundred thousand cells were
seeded in 60 mm diameter wells for RNA extraction, Western blot or flow
cytometry experiments. Cells were treated with 100 ng/ml TWEAK (Milli-
pore, Watford, UK), 1 ng/ml TGFb1 (Peprotech, London, UK), 100 nmol/l
Table 1 MXRA5 expression in different human tissues
n-fold P-value Reference
Kidney versus liver 1.57 0.009 [44]
Kidney versus heart 1.34 0.033 [44]
Kidney versus liver 3.12 0.001 GEO: GDS1663/209596
Kidney versus spleen 2.06 0.001 GEO: GDS1663/209596
Table 2 MXRA5 mRNA expression in human kidney disease according to publicly available transcriptomics datasets
Group n-fold P-value Reference
Clear cell sarcoma of the kidney versus control 4.79 0.003 [45]
Focal segmental glomerulosclerosis versus normal kidney/minimal change disease 4.58 0.001 [21]
Diabetic nephropathy versus healthy living donor (glomeruli) 1.96 0.05 [46]
Lupus Nephritis versus healthy living donor (tubulointerstitium) 1.75 0.043 [47]
Diabetic nephropathy versus minimal change disease 1.53 0.029 [48]
Rapidly progressive glomerulonephritis versus healthy living donor/minimal change disease (glomeruli) 1.48 0.018 [49]
Diabetic nephropathy versus healthy living donor/minimal change disease 1.47 0.008 [49]
Renal dysfunction versus healthy living donor 1.24 0.003 [50]
No significant differences were found for nephrosclerosis: glomeruli versus healthy glomeruli from tumour-free nephrectomy specimens [51] or
for renal cell carcinoma versus adjacent non-tumour tissue [52].
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paricalcitol (Abbot, Chicago, Illinois), 100 lmol/l TGFb1 receptor 1 (ALK5)
inhibitor (SB431542; Sigma-Aldrich, Sigma, St. Louis, MO) or 1 ng/ml
neutralizing anti-TGFb1 antibody (ab100NA; R&D Systems, Minneapolis,
MN), based on prior dose–responses studies from our lab.
Transfection of small interfering RNA
Cells were grown in six-well plates (Costar, Cambridge, MA, USA) and
transfected with a mixture of 30 nmol/ml MXRA5 siRNA (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), Opti-MEM I Reduced Serum Med-
ium and Lipofectamine RNAiMAX Transfection Reagent (Invitrogen, Life
technologies, Paisley, UK). After 18 hr, cells were washed and cultured
for 48 h in complete medium and serum-depleted for 24 hr before
stimulation. A scrambled siRNA (Ambion, Applied Biosystems, Foster
City, CA, USA) was used as control.
RNA extraction and real-time polymerase chain
reaction
Total RNA was extracted from cells by the TRI-Reagent method
(Sigma-Aldrich) and 1 lg RNA was reverse transcribed with High
Capacity cDNA Archive Kit (Applied Biosystems). Pre-developed primer
and probe assays for MXRA5, GAPDH, MCP-1, RANTES, CXCL16, Fibro-
nectin, Type IV Collagen and 18S were from Applied (Applied Biosys-
tems). Quantitative PCR was performed by 7500 Real-Time PCR
System with the Prism 7000 System SDS Software (Applied Biosys-
tems) and RNA expression of different genes was corrected for GAPDH
or 18S [12].
Western blot
Cell samples were homogenized in lysis buffer (50 mM Tris–HCl,
150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.2% Triton X-100, 0.3%
NP-40, 0.1 mM PMSF and 1 lg/ml pepstatin A) and then separated
by 15% SDS-PAGE under reducing conditions. After electrophoresis,
samples were transferred to PVDF membranes (Millipore), blocked
with 5% BSA in PBS/0.5% v/v Tween 20 for 1 hr, washed with PBS/
Tween, and incubated with goat polyclonal anti-MXRA5 (1:500 in 1%
BSA PBS/Tween; Santa Cruz Biotechnology). Blots were washed with
PBS/Tween and incubated with appropriate horseradish peroxidase-
conjugated secondary antibody (1:2000, Santa Cruz Biotechnology).
After washing with PBS/Tween, blots were developed with the chemi-
luminescence method (ECL) (Amersham). Blots were then probed with
mouse monoclonal anti-a-tubulin antibody (1:10,000; Sigma-Aldrich)
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Fig. 2MXRA5 is present in CKD patients.
(A) Urine supernatant. (B) Urine sediment.
Western blot shows bands recognized by
anti-MXRA5 antibody in urine of CKD
patients but not in healthy controls (N = 2
healthy controls and 3 CKD patients). (C)
MXRA5 mRNA expression in ADPKD cysts
or normal kidneys assessed by RT-qPCR
(N = 3 controls and 6 ADPKD patients,
*P < 0.001 versus control). (D) MXRA5
immunohistochemistry in ADPKD cysts or
normal kidneys (N = 6 controls and 6
ADPKD patients). Representative image.
(E) MXRA5 immunohistochemistry in
renal fibrosis and control kidney (N = 2
controls and 1 fibrotic, non-ADPKD
kidney).
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and levels of expression were corrected for minor differences in load-
ing [19].
Immunohistochemistry
Immunohistochemistry was carried out in paraffin-embedded human kid-
ney, fixed in 4% buffered formalin. The primary antibody was goat poly-
clonal anti-MXRA5 (1:100; Santa Cruz biotechnology). Briefly, 5-lm-thick
renal sections were adhered to polylysine-coated glass slides and fixed
overnight at 56°C. After deparaffinization through xylene, alcohol and dis-
tilled water, endogenous peroxidase was blocked by 3% H2O2 for 30 min.
Sections were microwaved in 0.1 mM citrate buffer pH 6.0 for 20 min.,
and transferred to distilled water. After rinsing in phosphate-buffered sal-
ine (PBS), sections were incubated with 1:10 normal donkey serum in
PBS/4% BSA and then incubated overnight at 4°C with goat anti-human
MXRA5. Next, they were incubated with biotinylated rabbit anti-goat anti-
body (1:300) in PBS–4% BSA for 30 min. at room temperature. After
three rinses in PBS, they were incubated with streptavidin–peroxidase
(Dako, Denmark) 1:500 for 30 min. Colour was developed with
diaminobenzidine and then counterstained with haematoxylin, dehydrated
and mounted with Canadian balsam (Polysciences). Specificity was
checked by omission of primary antibodies and use of non-immune sera.
Human kidney urine and tissue was obtained from the IIS-Fundacion
Jimenez Dıaz Biobank. Table S1 shows a clinical characterization of
patients.
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Fig. 3 TGFb1 increases MXRA5 in cultured
proximal tubular cells. (A) Human proxi-
mal tubular cells were exposed to 0.1, 1
and 10 ng/ml TGFb1 for 3 and 6 hr and
MXRA5 mRNA expression was assessed
by RT-qPCR (N = 3, *P < 0.001 versus
control, #P < 0.01 versus control). (B)
Cells were exposed to 1 ng/ml TGFb1 for
3, 6 and 24 hr and MXRA5 protein
expression was assessed by Western blot.
Tubulin was used as loading control
(N = 3, *P < 0.025 versus control,
#P < 0.05 versus control). (C) Cells were
pre-treated with 105 M TGFb1 receptor 1
inhibitor SB431542 for 1 hr and then
exposed to 1 ng/ml TGFb1 for 3 and 6 hr,
MXRA5 mRNA expression was assessed
by RT-qPCR (N = 3, *P < 0.001 versus
control, #P < 0.006 versus control). (D)
Cells were pre-treated with 105 M
SB431542 for 1 hr and then exposed to
1 ng/ml TGFb1 for 6 hr, MXRA5 protein
levels were assessed by Western blot
(N = 3, *P < 0.005 versus control). (E)
Cells were pre-treated with 1 ng/ml neu-
tralizing anti-TGFb1 antibody ab100NA for
1 hr and then exposed to 1 ng/ml TGFb1
for 3 and 6 hr, MXRA5 mRNA expression
was assessed by RT-qPCR (N = 3,
*P < 0.001 versus control). (F) Cells were
pre-treated with 1 ng/ml neutralizing anti-
TGFb1 antibody ab100NA for 1 hr and
then exposed to 1 ng/ml TGFb1 for 6 hr,
MXRA5 protein levels were assessed by
Western blot (N = 3, *P < 0.005 versus
control, #P < 0.018 versus control).
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Database search
The following databases were searched for MXAR5: Ensembl, ClinVar,
GEO profiles (http://www.ncbi.nlm.nih.gov/geoprofiles/?term=MXRA5+
kidney), Kidney & Urinary Pathway Knowledge Base (kupkb at http://
www.kupkb.org/) and nephromine (http://www.nephromine.org/).
Statistics
Statistical analysis was performed with SPSS 11.0 statistical software.
Results are expressed as mean  SEM for protein and mRNA expression
experiments. Significance at the P < 0.05 level was assessed by Stu-
dent’s t-test for two groups of data and ANOVA for three or more groups.
Results
MXRA5 is up-regulated in human kidney disease
MXRA5 is an evolutionary conserved gene. Although absent from
mouse and rat, MXRA5 is expressed in a wide range of human organs
and especially, in the normal human kidney (Fig. 1). The human kid-
ney has relatively high levels of MXRA5 mRNA as compared to other
organs [20] (Fig. 1B) (Table 1). In publicly available databases,
MXRA5 was found to be up-regulated in several forms of CKD, such
as focal segmental glomerulosclerosis (FSGS), diabetic nephropathy,
lupus nephritis, rapidly progressing glomerulonephritis and dysfunc-
tional transplanted kidneys as well as in clear cell sarcoma, while
there was no change in nephrosclerosis or renal cell carcinoma
(Table 2). Furthermore, the kupkb database reflected the finding of
MXRA5 in exosomes from normal urine in the Urinary Exosome Pro-
tein Database (http://dir.nhlbi.nih.gov/papers/lkem/exosome/).
According to Nephromine, in FSGS, the nephropathy with highest
MXAR5 expression, the best correlate of MXRA5 expression was the
expression of the TWEAK receptor, Fn14 (correlation 0.713) (Fig. 1C)
[21].
Consistent with transcriptomics databases, proteins immune-
reactive for anti-MXRA5 antibody were found both in the supernatant
and sediment of centrifuged unconcentrated urine in CKD patients
(samples 1-3; Table S1), but not in healthy controls (samples 4 and
5; Table S1) (Fig. 2A and B). Furthermore, MXRA5 mRNA expression
was increased in cysts from autosomal dominant polycystic kidney
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*P < 0.02 versus control, #P < 0.05 ver-
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disease (ADPKD) patients (Fig. 2C) and expression was localized to
cyst lining tubular cells by immunohistochemistry (Fig. 2D).
Immunohistochemistry also localized MXRA5 staining to tubular cells
in non-ADPKD kidney fibrosis (Fig. 2E, corresponding to samples
16–18; Table S1).
TGFb1 and paricalcitol regulate MXRA5
expression in cultured human tubular cells
After observing an up-regulation of MXAR5 expression in human
nephropathies characterized by kidney inflammation and fibrosis,
we explored the potential regulation of MXRA5 expression by a
representative fibrogenic cytokine TGFb1 and a representative pro-
inflammatory cytokine, TWEAK. Therapies targeting TWEAK and
TGFb1 are under clinical development. Despite the good correla-
tion between MXRA5 and Fn14 expression in FSGS, TWEAK did
not modulate MXRA5 mRNA levels in tubular cells (Fig. S1).
MXRA5 being an ECM protein, we next tested its regulation by
TGFb1. TGFb1 dose-dependently up-regulated MXRA5 mRNA
expression (Fig. 3A). The concentration of 1 ng/ml TGFb1 was
chosen for further studies. Stimulation of tubular cells with 1 ng/
ml TGF-b1 up-regulated MXRA5 protein levels in whole cells in a
time-dependent manner (Fig. 3B) TGFb1-induced MXRA5 up-regu-
lation was prevented by the TGFb1 receptor 1 (ALK5) inhibitor
SB431542 (Fig. 3C and D) and by the neutralizing anti-TGFb1 anti-
body ab100NA (Fig. 3E and F). Vitamin D has been shown to reg-
ulate kidney fibrosis. The vitamin D receptor activator paricalcitol
also inhibited the increase in MXRA5 mRNA (Fig. 4A) and protein
expression (Fig. 4B) induced by TGFb1.
MXRA5 has anti-inflammatory and anti-fibrotic
properties in cultured tubular cells
MXRA5 was knocked down by means of specific MXRA5 siRNA
(Fig. 5A and B). Down-regulation of MXRA5 did not alter the
morphological appearance of cells for up to 72 hr (Fig. 5C), and
changes in cell cycle or cell death were not observed upon MXRA5
down-regulation (Fig. 5D).
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As previously described, TWEAK elicited pro-inflammatory
responses in tubular cells [12, 22]. Down-regulation of MXRA5
resulted in increased expression of chemokine mRNA in response to
TWEAK stimulation (Fig. 6), as well as in increased MCP-1 protein
levels in cell supernatants (Fig. 6B), suggesting that endogenous
constitutive MXRA5 may play an anti-inflammatory role. TGFb1 is a
key fibrogenic cytokine in tubular cells and kidney injury [23]. MXRA5
down-regulation resulted in increased expression of genes encoding
the ECM proteins fibronectin and type IV collagen in response to
TGFb1 stimulation (Fig. 7), suggesting that TGFb1-induced MXRA5
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expression contributes to limit the fibrogenic response of tubular
cells. These results suggest that constitutive or inducible MXRA5 has
anti-inflammatory and anti-fibrotic properties.
MXRA5 in kidney cancer
As MXRA5 is overexpressed in ovarian, lung and colorectal cancer
[24–26], we studied MXRA5 expression in VHL-defective ccRCC cell
line (VHL/). MXRA5 mRNA expression was assessed in untreated
HK2 cells and VHL/ cells, as well as VHL-expressing ccRCC cells
(VHL+/+) (Fig. 8A). No MXRA5 mRNA expression was observed in
VHL/ cells, suggesting a relationship between MXRA5 and tumouri-
genesis. We then studied MXRA5 expression in renal biopsies from
renal carcinoma patients. We observed a direct relationship between
VHL and MXRA5 transcriptional expression (Fig. 8B). Thus, those
patients with low VHL expression showed low MXRA5 expression, as
observed for cultured ccRCC.
Discussion
The main finding of our study is that MXRA5 is an anti-inflammatory
and anti-fibrotic molecule up-regulated by the fibrogenic cytokine
TGFb1 in human proximal tubular cells. This knowledge may be used
to develop novel therapies for CKD.
CKD is characterized by inflammation and accumulation of
extracellular matrix and TWEAK and TGF-b1 were chosen as rep-
resentative pro-inflammatory and fibrogenic cytokines respectively.
Tubular cells are key cells in tubulointerstitial inflammation. In
response to an adverse microenvironment, tubular cells are acti-
vated to express chemotactic, pro-inflammatory and pro-fibrotic
molecules, including cytokines such as TNF, Fas ligand, TRAIL
and TWEAK and chemokines such as MCP-1, RANTES and
CXCl16 that decisively contribute to recruit inflammatory cells
and to promote kidney injury [12, 22, 27, 28]. In this regard,
tubulointerstitial damage correlates better with outcome of renal
function than glomerular injury scores, even for primary glomeru-
lonephritis [29]. Indeed, tubulointerstitial fibrosis is considered an
important predictor of renal survival [30] and TGFb1 is a key
pro-fibrotic cytokine that contributes to renal fibrosis [31–33],
while TWEAK is a key pro-inflammatory cytokine which promotes
glomerular and tubulointerstitial inflammation and fibrosis [12].
Up-regulation of TGF-b1 is a universal finding in CKD, both in
animal models and in humans. Inhibition of TGFb1 by multiple
strategies suppresses renal fibrotic lesions and prevents progres-
sive loss of kidney function [34]. Interestingly, TGFb1 also has
anti-inflammatory actions. Indeed, TGF-b1 KO mice display a sys-
temic inflammatory disease, causing, among others, kidney
inflammation [35]. We have now observed that TGFb1, but not
the inflammatory cytokine TWEAK, up-regulated MXRA5 expres-
sion in tubular cells through the activation of the TGFR1 recep-
tor. This suggests that MXRA5 might mediate some TGFb1
actions. In this regard siRNA targeting of MXRA5 led to a strik-
ing increase in the pro-inflammatory response to TWEAK. Thus,
MXRA5, as TGFb1, behaves as an anti-inflammatory molecule in
tubular cells. By contrast, MXRA5 targeting magnified TGFb1-
induced expression of ECM genes, suggesting that MXRA5 may
also limit some TGFb1-elicited responses, such as fibrosis. Over-
all, the dual anti-inflammatory and anti-fibrotic activity of MXRA5
suggests that this is a molecule of potential therapeutic interest
and that MXRA5 up-regulation in CKD may be an adaptive
response that breaks inflammation and fibrosis. In this regard,
characterization of the MXRA5 receptor and generation of agonis-
tic peptides may provide a new avenue for research in kidney
disease. However, the fact that mice and rats do not express
MXRA5 will complicate the development of preclinical models to
address its in vivo function in kidney disease. The observation
that the VDR activator paricalcitol prevents MXRA5 up-regulation
in response to TGFb1 is especially interesting. Thus, paricalcitol
has anti-inflammatory and anti-fibrotic properties that may com-
pensate for the loss of the anti-inflammatory and anti-fibrotic
action of MXRA5 [36, 37]. Thus, paricalcitol directly decreased
the expression of cytokines and extracellular matrix and moder-
ated Wnt/b-catenin signalling and NF-jB and Snail activation in
cultured renal cells [36–40]. While nephroprotective actions of
VDR activation have been observed in numerous rat and mice
models, human confirmation is lacking [41]. Among the potential
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Fig. 8MXRA5 in cancer. (A) Human proximal tubular cells and VHL/
and VHL+/+ clear cell carcinoma cells were serum-depleted and collected
at 1, 3, 6 and 24 hr. MXRA5 mRNA expression was assessed by RT-
qPCR (N = 3). (B) MXRA5 and VHL mRNA expression assessed in
biopsies from renal carcinoma tissue (N = 10) and healthy kidney tis-
sue (n = 9) from the same kidney (*P < 0.05).
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explanations for this discrepancy, we should now add the lack of
MXRA5 in rats and mice used as models of kidney disease,
while this potentially nephroprotective molecule is present in
humans and down-regulated by VDR activators. Thus, we specu-
late that the coexistence of nephroprotective and non-nephropro-
tective actions of paricalcitol may be one of the contributing
factors to the clinical failure of paricalcitol in kidney disease.
Urine contained anti-MXRA5 immunoreactive peptides that
may correspond to proteolytic fragments of MXRA5. Their pres-
ence in urine from CKD patients may point to a potential role as
a biomarker. However, given the diverse sizes of the bands
observed, this result should be considered preliminary. In this
regard, increased tubular cell expression of MXRA5 was observed
in human CKD tissue. The finding of MXRA5 in normal urine
exosomes [42] may account for its presence in urine and might
even contribute to its biological activity.
The present findings may also be relevant for cancer. MXRA5
was found overexpressed in ovarian cancer compared with nor-
mal ovaries and it was involved in tumour angiogenesis [24]. It
is also among the most frequently mutated genes in non-small
cell lung carcinomas [25]. MXRA5 was proposed as a novel bio-
marker in colorectal cancer [26], as it was overexpressed in col-
orectal cancer tissue compared with their corresponding normal
tissue [26, 43]. Our results further show that VHL may be a dri-
ver of MXRA5 expression in cancer cells.
In conclusion, MXRA5 is a molecule involved in the regulation
of important biological processes, such as inflammation and
fibrosis, during kidney disease. Additional studies will be required
to determine the clinical relevance of MXRA5 as a biomarker in
renal disease as well as to better characterize the molecular
determinants of MXRA5 action, including the search for
receptors.
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